Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Cell Cycle >  CDK inhibitors >  JNJ-7706621

JNJ-7706621

Basic information Safety Supplier Related

JNJ-7706621 Basic information

Product Name:
JNJ-7706621
Synonyms:
  • 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide JNJ7706621
  • 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide
  • Aurora Kinase/Cdk Inhibitor
  • Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem
  • CS-409
  • JNJ7706621; JNJ 7706621
  • Benzenesulfonamide, 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-
  • 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide
CAS:
443797-96-4
MF:
C15H12F2N6O3S
MW:
394.36
Product Categories:
  • Inhibitor
  • Inhibitors
Mol File:
443797-96-4.mol
More
Less

JNJ-7706621 Chemical Properties

Melting point:
149-155℃
Boiling point:
676.6±65.0 °C(Predicted)
Density 
1.71
storage temp. 
+2C to +8C
solubility 
Soluble in DMSO at 15mg/ml
form 
White solid
pka
9.80±0.12(Predicted)
Sensitive 
Light Sensitive
More
Less

JNJ-7706621 Usage And Synthesis

Description

JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDKs) and Aurora kinases. It potently inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC50s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, respectively). It shows selectivity for these enzymes over a panel of other receptors and kinases, although it exhibits submicromolar inhibition of VEGF and FGF receptors, as well as GSK3β. JNJ-7706621 blocks the growth of a large variety of cancer cell lines (IC50 values range from 112 to 514 nM), with lower potency against normal cells (IC50 values between 3.67 and 5.42 μM). It induces the regression of A375 melanoma human tumor xenografts in mice. JNJ-7706621 is a substrate for the ATP-binding cassette transporter G2, also known as breast cancer resistance protein.

Uses

JNJ-770662 is a broad spectrum inhibitor of cyclin-dependent kinases and aurora kinases including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A and Aurora-B. JNJ-770662 has been shown to induce growth suppression and mitotic defects, these results suggest that JNJ-7706621 could be useful for cell cycle analysis and therapy of various cancers, including Ewing''s sarcoma.

Definition

ChEBI: 4-[[5-amino-1-[(2,6-difluorophenyl)-oxomethyl]-1,2,4-triazol-3-yl]amino]benzenesulfonamide is a sulfonamide.

target

CDK1

JNJ-7706621Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
VDM Biochemicals
Tel
0330-2528181
Email
sales@vdmbio.com
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Email
info@chemlin.com.cn
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Email
sales@trio-pharmatech.com (International market)